Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
BEFREE |
Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma.
|
28284458 |
2017 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
ATM mutation and radiosensitivity: An opportunity in the therapy of mantle cell lymphoma.
|
27823642 |
2016 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
BEFREE |
A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
|
25232030 |
2015 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The MEC-1 and GRANTA-519 cells can be especially recommended for in vivo study of p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma, respectively.
|
25827173 |
2015 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
BEFREE |
We previously reported that mantle cell lymphoma cells with deficiency in ataxia telangiectasia mutated (ATM) are sensitive to PARP-1 inhibitors in vitro and in vivo.
|
24841718 |
2014 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
BEFREE |
Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
|
22170260 |
2012 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer.
|
19781682 |
2009 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.
|
16461462 |
2006 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The cell cycle, the ATM, gene and the nuclear factor kappaB pathways are the main targets of the genetic abnormalities occurring in mantle cell lymphoma: new genomic and expression data have been recently published.
|
15548996 |
2004 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
BEFREE |
In B-chronic lymphocytic leukemia and mantle cell lymphoma we observed two categories: ATM-negative tumors, most likely reflecting the presence of ATM mutation, and tumors with abundant ATM expression.
|
12875964 |
2003 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
|
11756177 |
2002 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
BEFREE |
The ATM gene in the pathogenesis of mantle-cell lymphoma.
|
10707794 |
2000 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
A hemizygous ATM deletion was seen in 44% to 88% of the interphase cells in 15 cases (11.1%); four patients had an indolent lymphoma (follicular center cell lymphoma), and 11 patients had an aggressive lymphoma (five mantle-cell lymphomas [MCLs] and six diffuse large-cell lymphomas).
|
10893293 |
2000 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
To investigate a potential pathogenic role of ATM in B-cell tumorigenesis, we performed mutation analysis of ATM in 29 malignant lymphomas of B-cell origin (B-CLL = 27; mantle cell lymphoma, [MCL] = 2).
|
10397742 |
1999 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
PosttranslationalModification
|
disease |
BEFREE |
Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma.
|
10556216 |
1999 |
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|